Nature Communications (Nov 2022)

Safety and immunogenicity following a homologous booster dose of CoronaVac in children and adolescents

  • Lei Wang,
  • Zhiwei Wu,
  • Zhifang Ying,
  • Minjie Li,
  • Yuansheng Hu,
  • Qun Shu,
  • Jing Li,
  • Huixian Wang,
  • Hengming Zhang,
  • Wenbin Jiao,
  • Lin Wang,
  • Yuliang Zhao,
  • Qiang Gao

DOI
https://doi.org/10.1038/s41467-022-34280-y
Journal volume & issue
Vol. 13, no. 1
pp. 1 – 9

Abstract

Read online

Few countries have approved SARS-CoV-2 booster doses in children and adolescents due to insufficient evidence about the safety and interval vaccination. Here, the authors assess the safety and immunogenicity of a homologous booster dose of CoronaVac in a cohort of 3–17 year olds.